Repealing the IMD Exclusion Act

This bill directly amends the Social Security Act to remove the Institution for Mental Diseases (IMD) exclusion, which currently prohibits federal Medicaid payments for services provided to individuals aged 21-64 in mental health or substance use disorder facilities with more than 16 beds. The legislation eliminates the age limitation and the bed count restriction, allowing any institution primarily treating mental diseases or substance use disorders to qualify for Medicaid reimbursement if it meets nationally recognized, evidence-based standards. This change immediately opens up a significant new revenue stream for mental health and substance use disorder treatment providers that were previously limited by the IMD exclusion. The money trail for this legislation is direct: it enables Medicaid funds to flow to a broader range of mental health and substance use disorder treatment facilities. Currently, states often use waivers to circumvent the IMD exclusion, but this bill codifies direct federal payment, simplifying the process and increasing the certainty of reimbursement. Companies operating inpatient mental health and substance use disorder facilities, particularly those with more than 16 beds, stand to gain. This includes large hospital systems and specialized behavioral health providers. The bill specifies that facilities must meet nationally recognized standards, such as those from the American Society of Addiction Medicine, which benefits established, accredited providers. Historically, efforts to repeal or modify the IMD exclusion have been ongoing. While a full repeal has not passed, states have increasingly used waivers to expand Medicaid coverage for IMD services. For example, in 2018, CMS issued guidance allowing states to use Section 1115 waivers to cover IMD services for substance use disorder treatment, leading to increased state spending and provider revenue in participating states. While direct market data for a full repeal is unavailable, the expansion of Medicaid coverage for behavioral health services generally correlates with increased utilization and revenue for providers. For instance, when Medicaid expansion under the Affordable Care Act began, states that expanded saw a significant increase in behavioral health service utilization, benefiting providers. While specific stock movements tied solely to IMD waiver approvals are difficult to isolate, the general trend is that increased Medicaid access to services boosts provider financials. Specific winners include large behavioral health providers such as Universal Health Services ($UHS), which operates numerous psychiatric hospitals and behavioral health facilities. Acadia Healthcare Company ($ACAD) and Behavioral Health Group also stand to gain significantly as their facilities become eligible for direct Medicaid reimbursement for a broader patient population. Laboratory Corporation of America Holdings ($LH) could see increased demand for diagnostic testing related to mental health and substance use disorders as more patients access treatment. The bill's sponsor, Rep. Torres, a Democrat, indicates support from within the party, and its referral to Energy and Commerce, a key health committee, suggests it is on a relevant legislative path. The bill's passage would immediately expand the total addressable market for these services. The next step is committee consideration. Given the bill's referral to the House Committee on Energy and Commerce, it will undergo review and potential amendments there. If it passes committee, it moves to a full House vote. The timeline for this process is uncertain but could extend through 2026. If enacted, the changes would take effect immediately upon becoming law, directly impacting provider reimbursement and patient access.